EGFR Pathway Markers and Prognosis in Lung Cancer
Author Information
Author(s): Ruiz M I Galleges, Floor K, Steinberg S M, Grünberg K, Thunnissen F B J M, Belien J A M, Meijer G A, Peters G J, Smit E F, Rodriguez J A, Giaccone G
Primary Institution: VU University Medical Center, Amsterdam, The Netherlands
Hypothesis
The combined analysis of several molecular markers related to the EGFR pathway is related to the prognosis of NSCLC patients when analyzed in combination.
Conclusion
The study found that certain EGFR-related markers are associated with survival in NSCLC patients.
Supporting Evidence
- EGFR mutations were found in 4% of patients.
- KRAS mutations were observed in 18% of patients.
- High expression of pCMET is related to poor prognosis.
- High expression of E-cadherin is related to improved outcome.
- Markers like KRAS mutation and cytoplasmic EGFR were associated with survival.
Takeaway
This study looked at different markers in lung cancer to see how they affect patient survival. It found that some markers can help predict how well patients will do.
Methodology
The study analyzed tumor specimens for EGFR and KRAS mutation status and EGFR copy number, using DNA sequencing and immunohistochemistry.
Limitations
The findings are exploratory and may not apply to patients receiving adjuvant chemotherapy.
Participant Demographics
{"gender":{"male":127,"female":51},"histology":{"adenocarcinoma":64,"squamous_cell_carcinoma":77,"large_cell_carcinoma":24},"smoking_status":{"never":3,"former":70,"current":60},"tumor_stage":{"stage_I":90,"stage_II":52,"stage_III":36}}
Statistical Information
P-Value
0.00015
Statistical Significance
p=0.00015
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website